How Does Parkinson’s Prevalence Differ Across Continents, What Percentage of Adults Are Affected in Asia, Europe, and North America, and How Do Healthcare Responses Differ? 🌍🧠

This article is written by mr.hotsia, a long term traveler and storyteller who runs a YouTube travel channel followed by over a million followers. Over the years he has crossed borders and backroads throughout Thailand, Laos, Vietnam, Cambodia, Myanmar, India and many other Asian countries, sleeping in small guesthouses, village homes and roadside inns. Along the way he has listened to real life health stories from locals, watched how people actually live day to day, and collected simple lifestyle ideas that may help support better wellbeing in practical, realistic ways.

When people ask whether Parkinson’s is more common in one continent than another, the answer is yes, but the map is not perfectly clean. Prevalence estimates differ not only because the disease burden is different, but also because the studies use different age ranges, case-finding methods, and regional groupings. Some reports measure all ages, some focus on adults over 45, and some use age-standardised rates. So the safest way to compare continents is to treat the numbers as informed approximations, not as identical apples stacked in identical baskets.

The broad pattern is this: Europe and parts of North America tend to report relatively high Parkinson’s prevalence, while Asia is more mixed, with some Asian subregions, especially East Asia, now showing burdens that rival or exceed many Western regions. A 2024 Lancet Healthy Longevity meta-analysis reported the highest all-age prevalence in the WHO European region at 1.80 cases per 1,000 people, while newer Asia-focused burden work found Asia’s age-standardised prevalence averaged 154.44 per 100,000 in 2021, with East Asia much higher at 243.46 per 100,000. In North America, a pooled estimate across several regions found a prevalence of 572 per 100,000 among adults aged 45 years and older.

What percentage of adults are affected in Asia, Europe, and North America?

Here is the clearest practical translation of those figures into percentages:

• Asia: about 0.154% on an age-standardised basis overall, with East Asia around 0.243%.

• Europe: about 0.18% in the WHO European region from the 2024 global meta-analysis.

• North America: about 0.572% among adults aged 45 and older in a pooled North American estimate.

That North American figure looks higher partly because it is drawn from a middle-aged-and-older adult population rather than the whole population. Parkinson’s rises sharply with age, so any estimate limited to adults 45 and older will naturally look heavier than an all-age estimate. This is why direct continent-to-continent comparison can mislead if the age bands are not matched. The same global reviews show prevalence climbing steeply in later life, which is one reason every aging society begins to feel Parkinson’s more heavily over time.

Asia: lower in some places, rising fast in others

Asia is not one Parkinson’s story. It is many stories stitched together. Older reviews often described Parkinson’s prevalence in Asia as similar to or somewhat lower than Europe and North America, but more recent work shows that the burden in Asia has risen sharply, and East Asia now stands out with especially high age-standardised prevalence. A 2025 review of GBD 2021 data reported that East Asia had the highest age-standardised prevalence among the 21 GBD geographic regions at 243.46 per 100,000. Meanwhile, the Asia-wide analysis found the continental average at 154.44 per 100,000, already above the global average.

This matters because Asia contains both high-capacity urban health systems and lower-resource settings where underdiagnosis is still a real issue. A 2024 review focused on the Western Pacific and Thailand warned that many early-stage cases remain undiagnosed, precisely at the stage when intervention would likely be most valuable and least costly. The same review argued that low- and middle-income settings may lack the resources to meet the growing need. So Asia’s problem is not only more Parkinson’s. It is also more Parkinson’s arriving in systems that are not equally ready to respond.

Europe: high measured prevalence and stronger organised care networks

Europe often shows up near the top of prevalence charts, and the 2024 Lancet meta-analysis placed the WHO European region highest at 1.80 per 1,000. That does not necessarily mean Europe is biologically unique. Part of it likely reflects older populations, longer survival, broader diagnosis, and more mature case registration systems. Better detection can make burden appear larger because it is being seen more clearly.

Where Europe often differs most clearly is in how care is organised. European Parkinson’s care has put major emphasis on integrated, multidisciplinary models, with neurologists, physiotherapists, occupational therapists, speech therapists, psychologists, and nurses working in more coordinated ways. ParkinsonNet and related network-based ideas have become an influential example of how chronic neurological care can be reorganised around expertise, continuity, and patient-centred delivery. More recent European policy documents also push telemedicine, monitoring technology, and cross-system data sharing to make care more sustainable as case numbers rise.

In plain language, Europe often looks less like a single doctor-and-prescription model and more like a team sport. That does not mean access is perfect. Even in systems with universal coverage, disparities remain, including unequal access for minority ethnic groups and uneven local availability of specialised care. But the direction of travel in Europe is clearly toward structured multidisciplinary care rather than isolated symptom-by-symptom treatment.

North America: substantial burden, specialist excellence, but patchy access

North America also carries a heavy Parkinson’s load. The pooled prevalence estimate of 572 per 100,000 among adults aged 45 and older suggests a meaningful public health burden already in place, and the same study projected major growth as the population ages. Even the authors cautioned that their figure may be a minimum estimate because medical-record-based studies miss people who never reach specialist care or who are not coded correctly in health systems.

North America’s healthcare response often revolves around specialist centres, hospital quality initiatives, rehabilitation, and large advocacy-driven ecosystems. In the United States, the Parkinson’s Foundation has developed hospital care initiatives and broader patient-centred care strategies aimed at preventing medication delays, reducing hospital harm, and expanding better systems of care. Academic centres and multidisciplinary clinics are prominent. But there is an important crack in the floorboards: the Parkinson’s Foundation recently highlighted a growing shortage of neurologists and reported that fewer than 10% of people with Parkinson’s receive care from a movement disorders specialist.

So North America often has very high-end care available, but not evenly distributed. It can look like a continent with superb lighthouses on the coast and fog in between. The centres of excellence are real. The access gaps are real too.

Why prevalence differs across continents

There are several reasons these continental differences appear. First, age structure matters. Parkinson’s is strongly age-related, so older populations naturally show more cases. Second, survival matters. Better healthcare can raise prevalence because people live longer with the disease. Third, diagnosis and ascertainment matter. Regions with more neurologists, better registries, and more access to specialist assessment may record more cases that would go uncounted elsewhere. Fourth, genetics, environmental exposures, urbanisation, and possibly pesticide patterns may also contribute, although these explanations are more complex and not fully settled.

That is why high prevalence is not automatically bad news in a simple sense. Sometimes it partly reflects better detection and longer survival. Low prevalence is not automatically reassuring either. In some settings, it can mean under-recognition, shorter survival, or weaker case capture. The number is important, but the healthcare context around the number matters just as much.

How healthcare responses differ in practical terms

If we strip away the academic language, the continental differences in response look something like this.

In Asia, the main themes are rapid growth in burden, uneven access, underdiagnosis in some countries, and pressure to build stronger chronic disease systems, early detection, and sustainable long-term care. Digital screening and scalable public health tools are receiving attention because specialist capacity is not equally available everywhere.

In Europe, the main themes are integrated care, multidisciplinary rehabilitation, network models like ParkinsonNet, and stronger policy interest in telemedicine and coordinated cross-disciplinary care. Europe’s challenge is less about whether Parkinson’s needs team-based care and more about how to deliver that model consistently and equitably.

In North America, the main themes are specialist-led centres, strong advocacy organisations, hospital care improvement efforts, and advanced clinical infrastructure, but with persistent problems in access, geography, workforce shortages, and the fact that many patients still never reach a movement-disorder specialist.

The bottom line

Parkinson’s prevalence does differ across continents, but the exact ranking depends on which age groups and methods are being compared. Using recent sources, Europe sits around 0.18% in the 2024 WHO-region meta-analysis, Asia averages about 0.154% on an age-standardised basis with East Asia higher at about 0.243%, and North America shows about 0.572% among adults aged 45 and older in pooled data. These are best read as useful approximations rather than perfect like-for-like comparisons.

Healthcare responses differ too. Asia is wrestling with rapidly rising burden and uneven access. Europe is leaning hard into integrated multidisciplinary networks. North America has powerful specialist centres and advocacy-driven innovation, but also patchy access and workforce shortages. So the map of Parkinson’s is not only a map of disease. It is also a map of how health systems notice it, count it, and answer it.

FAQs: Parkinson’s Prevalence Across Continents

1. Which continent has the highest Parkinson’s prevalence?

Using the 2024 Lancet Healthy Longevity meta-analysis by WHO region, the European region had the highest all-age prevalence at 1.80 cases per 1,000 people, though some Asian subregions such as East Asia are also very high in newer GBD analyses.

2. What percentage of adults are affected in Asia?

A recent Asia-specific GBD 2021 analysis estimated the average age-standardised prevalence in Asia at 154.44 per 100,000, which is about 0.154%, with East Asia higher at 243.46 per 100,000, or about 0.243%.

3. What percentage of adults are affected in Europe?

The 2024 global meta-analysis estimated Parkinson’s prevalence in the WHO European region at 1.80 per 1,000 people, which is about 0.18%.

4. What percentage of adults are affected in North America?

A pooled North American estimate found 572 cases per 100,000 adults aged 45 and older, which is about 0.572%. This figure is not directly comparable with all-age estimates because it focuses on an older adult population.

5. Why are these percentages not perfectly comparable?

Because the studies use different age ranges, standardisation methods, and regional definitions. Parkinson’s rises steeply with age, so older study populations will always show higher percentages.

6. Is Parkinson’s rising faster in Asia?

In many analyses, yes. Asia’s burden has grown sharply, and East Asia in particular shows a very strong increase in prevalence over time.

7. How does Europe usually respond to Parkinson’s care?

Europe tends to emphasise integrated multidisciplinary care, including coordinated neurology, rehabilitation, nursing, and allied health support, often through network-style models.

8. How does North America usually respond?

North America relies heavily on specialist centres, advocacy-led programmes, hospital care initiatives, and multidisciplinary clinics, but access remains uneven and workforce shortages are an issue.

9. What is the main healthcare challenge in Asia?

The big challenge is the combination of rapidly increasing burden, underdiagnosis in some areas, and uneven specialist resources, especially in low- and middle-income settings.

10. What is the simplest way to understand the continental picture?

Europe often looks like the best-organised orchestra, North America like a stage with brilliant soloists but uneven ticket access, and Asia like a fast-growing audience arriving faster than many clinics can seat them. The music is the same disease. The venue changes the experience.

I’m Mr.Hotsia, sharing 30 years of travel experiences with readers worldwide. This review is based on my personal journey and what I’ve learned along the way. Learn more